Comprehensive mCSPC Management for Urologists: Debunking Myths, Optimizing Outcomes, and Supporting Patient-Centred Intensification

Speakers: Scott Edwards, Avril Lusty & Ricardo Rendon

Objectives

By the end of this program, participants can expect to:

• Interpret efficacy endpoints in mCSPC treatment with ARPIs to guide treatment decisions for long-term success.
• Analyze ADT and ARPI safety and AE data, focusing on trial methodologies and patient-reported outcomes, to inform treatment decisions that balance efficacy and QoL in mCSPC patients.
• Understand the unique DDI profiles of ARPIs and their impact on urology medications to optimize treatment selection in mCSPC.
• Collaborate with multidisciplinary teams to manage DDIs and AEs, using tools such as DDI reference guides and checklists to optimize patient care and reduce polypharmacy risks.

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

This program has received financial support from Johnson&Johnson  in the form of an educational grant.